Antithrombotic therapy for prevention of various thrombotic diseases

Drug Development Research

Volumn 74, Issue 8, 2013, Pages 568-574

  Goto, Shinya ^a   Tomita, Aiko ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

anticoagulant; antiplatelet; antithrombotics; aspirin; new oral anticoagulants; warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; THIENOPYRIDINE DERIVATIVE; WARFARIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART VALVE REPLACEMENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RISK REDUCTION; STENT THROMBOSIS; THROMBOCYTE ACTIVATION; THROMBOSIS; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 84890562783     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21116     Document Type: Review

References (51)

1. Alberts MJ, Bhatt DL, Smith SC Jr, Rother J, Goto S, Hirsch AT, Steg PG, Investigators RR,. 2011. Risk factors and outcomes for patients with vascular disease and serious bleeding events. Heart 97: 1507-1512.
2. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, et al. 2009. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373: 1849-1860.
3. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liau CS, Richard AJ, Rother J, et al. 2006. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 295: 180-189.
4. Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, Wilson PW, Alberts MJ, D'Agostino R, Liau CS, et al. 2010. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 304: 1350-1357.
5. Brighton TA, Eikelboom JW, Mann K, Mister R, Gallus A, Ockelford P, Gibbs H, Hague W, Xavier D, Diaz R, et al. 2012. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 367: 1979-1987.
6. Burke TA, Venketasubramanian RN,. 2006. The epidemiology of stroke in the East Asian region: a literature-based review. Int J Stroke 1: 208-215.
7. CAPRIE Steering Committee. 1996. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348: 1329-1339.
8. Committee I-S. 1988. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 2: 349-360.
9. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, et al. 2009. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361: 1139-1151.
10. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, et al. 2011. Apixaban in patients with atrial fibrillation. N Engl J Med 364: 806-817.
11. Goto S,. 2004a. Propagation of arterial thrombi: local and remote contributory factors. Arterioscler Thromb Vasc Biol 24: 2207-2208.
12. Goto S,. 2004b. Understanding the mechanism and prevention of arterial occlusive thrombus formation by anti-platelet agents. Curr Med Chem Cardiovasc Hematol Agents 2: 149-156.
13. Goto S,. 2004c. Understanding the mechanism of platelet thrombus formation under blood flow conditions and the effect of new antiplatelet agents. Curr Vasc Pharmacol 2: 23-32.
14. Goto S,. 2005. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl 6: 3-11.
15. Goto S,. 2008a. Blood constitution: platelet aggregation, bleeding, and involvement of leukocytes. Rev Neurol Dis 5: S22-S27.
16. Goto S,. 2008b. Cardiovascular risk factors in patients at high risk of atherothrombosis: what can be learned from registries? Thromb Haemost 100: 611-613.
17. Goto S, Toda E,. 2009. Antiplatelet therapy after coronary intervention in Asia and Japan: the Asian perspective of antiplatelet intervention. Hamostaseologie 29: 321-325.
18. Goto S, Ikeda Y, Murata M, Handa M, Takahashi E, Yoshioka A, Fujimura Y, Fukuyama M, Handa S, Ogawa S,. 1992. Epinephrine augments von Willebrand factor-dependent shear-induced platelet aggregation. Circulation 86: 1859-1863.
19. Goto S, Tamura N, Eto K, Ikeda Y, Handa S,. 2002. Functional significance of adenosine 5'-diphosphate receptor (P2Y(12)) in platelet activation initiated by binding of von Willebrand factor to platelet GP Ibalpha induced by conditions of high shear rate. Circulation 105: 2531-2536.
20. Goto S, Tamura N, Ishida H, Ruggeri ZM,. 2006. Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5'-diphosphate receptor stimulation and cyclic calcium signaling. J Am Coll Cardiol 47: 155-162.
21. Goto S, Bhatt DL, Rother J, Alberts M, Hill MD, Ikeda Y, Uchiyama S, D'Agostino R, Ohman EM, Liau CS, et al. 2008. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J 156: 855-863, 863 e2.
22. Goto S, Ikeda Y, Shimada K, Uchiyama S, Origasa H, Kobayashi H, Investigators JT,. 2011a. One-year cardiovascular event rates in Japanese outpatients with myocardial infarction, stroke, and atrial fibrillation. -Results From the Japan Thrombosis Registry for Atrial Fibrillation, Coronary, or Cerebrovascular Events (J-TRACE). Circ J 75: 2598-2604.
23. Goto S, Hankey G, Hills T, Hu D, Lip GYH, Lobban MBET, Quek DKL, Sim KH, Tanahashi N, Tse HF, et al. 2011b. How can we avoid a stroke crisis in the Asia-Pacific region? London: Action for Stroke Prevention.
24. Goto SI, Ikeda Y, Chan JC, Wilson PWF, Yeo TC, Liau CS, Abola MT, Salette G, Steg PG, Bhatt DL, on behalf of the REACH Registry Investigators. 2011c. Risk-factor profile, drug usage and cardiovascular events within a year in patients with and a high risk of atherothrombosis recruited from Asia as compared with those recruited from non-Asia regions: a substudy of the REduction of Atherothrombosis for Continued Health (REACH) registry. Heart Asia 3: 93-98.
25. Goto S, Serebruany V,. 2011. Vorapaxar. Drugs Future 36: 101-113.
26. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, et al. 2011. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365: 981-992.
27. Group ATC. 1994. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 308: 81-106.
28. Group ATC. 2002. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324: 71-86.
29. Group PHSR. 1989. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 321: 129-135.
30. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, et al. 2001. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409: 202-207.
31. Hori M, Connolly SJ, Zhu J, Liu LS, Lau CP, Pais P, Xavier D, Kim SS, Omar R, Dans AL, et al. 2013. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke 44: 1891-1896.
32. Hoshiba Y, Hatakeyama K, Tanabe T, Asada Y, Goto S,. 2006. Co-localization of von Willebrand factor with platelet thrombi, tissue factor and platelets with fibrin, and consistent presence of inflammatory cells in coronary thrombi obtained by an aspiration device from patients with acute myocardial infarction. J Thromb Haemost 4: 114-120.
33. Kawamura Y, Takahari Y, Tamura N, Eguchi Y, Urano T, Ishida H, Goto S,. 2009. Imaging of structural changes in endothelial cells and thrombus formation at the site of FeCl(3)-induced injuries in mice cremasteric arteries. J Atheroscler Thromb 16: 807-814.
34. Kubo M, Hata J, Doi Y, Tanizaki Y, Iida M, Kiyohara Y,. 2008. Secular trends in the incidence of and risk factors for ischemic stroke and its subtypes in Japanese population. Circulation 118: 2672-2678.
35. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, et al. 1998. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 339: 1665-1671.
36. Maeda K, Toyoda K, Minematsu K, Kobayashi S,; Japan Standard Stroke Registry Study Group. 2012. Effects of sex difference on clinical features of acute ischemic stroke in Japan. J Stroke Cerebrovasc Dis 312: 82-85.
37. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE,. 2007. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356: 1020-1029.
38. Nabel EG, Braunwald E,. 2012. A tale of coronary artery disease and myocardial infarction. N Engl J Med 366: 54-63.
39. Pare G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Hirsh J, Simonsen K, Bhatt DL, Fox KA, Eikelboom JW,. 2010. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 363: 1704-1714.
40. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, et al. 2011. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365: 883-891.
41. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C,. 2005. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353: 2373-2383.
42. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, et al. 2010. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 9: 959-968.
43. Steg PG, Bhatt DL, Wilson PW, D'Agostino R Sr, Ohman EM, Rother J, Liau CS, Hirsch AT, Mas JL, Ikeda Y, et al. 2007. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 297: 1197-1206.
44. Tamura N, Kitajima I, Kawamura Y, Toda E, Eguchi Y, Ishida H, Goto S,. 2009. Important regulatory role of activated platelet-derived procoagulant activity in the propagation of thrombi formed under arterial blood flow conditions. Circ J 73: 540-548.
45. Verheugt FW,. 2006. Good old warfarin for stroke prevention in atrial fibrillation. Lancet 367: 1877-1878.
46. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al. 2009. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361: 1045-1057.
47. Warkentin TE,. 2012. Aspirin for dual prevention of venous and arterial thrombosis. N Engl J Med 367: 2039-2041.
48. Weitz JI, Buller HR,. 2002. Direct thrombin inhibitors in acute coronary syndromes: present and future. Circulation 105: 1004-1011.
49. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, et al. 2007. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357: 2001-2015.
50. Yamaguchi T,. 2000. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Stroke 31: 817-821.
51. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK,; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. 2001. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345: 494-502.